Biogen submits hemophilia A drug for FDA approval

03/13/2013 | RTT News

Biogen Idec has filed a biologics license application with the FDA for approval to use recombinant factor VIII Fc fusion protein as a treatment for hemophilia A. The drug belongs to a new class of long-lasting clotting factor treatments. The application was based on positive results of the late-stage A-LONG trial.

View Full Article in:

RTT News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations